Prostate Cancer - Results from #26520

Detailed results from ALSYMPCA phase III study highlight the positive impact of Alpharadin (radium-223 chloride) on skeletal related events associated with bone metastases from castration resistant prostate cancer February 8, 2012

GU Cancers Symposium 2012 - Prostate cancer: Take home message - Session Highlights February 8, 2012

GU Cancers Symposium 2012 - mCRPC opportunities for the urologist and radiation oncologist: An interview with Adam M. Kibel, Chairman, GU Cancers Symposium - Session Highlights February 8, 2012

GU Cancers Symposium 2012 - Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA) - Session Highlights February 8, 2012

Dietary calcium and risk for prostate cancer: A case-control study among US veterans - Abstract February 7, 2012

Risk profiles of prostate cancers identified from UK primary care using national referral guidelines - Abstract February 7, 2012

BCAR1 expression improves prediction of biochemical reccurence after radical prostatectomy - Abstract February 7, 2012

Graph based fusion of miRNA and mRNA expression data improves clinical outcome prediction in prostate cancer - Abstract February 7, 2012

Infectious complications and hospital admissions after prostate biopsy in a European randomized trial - Abstract February 7, 2012

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy - Abstract February 7, 2012

Radical prostatectomy: Positive surgical margins matter - Abstract February 7, 2012

Radioactive seed migration after transperineal interstitial prostate brachytherapy and associated development of small-cell lung cancer - Abstract February 7, 2012

Effect of gold marker seeds on magnetic resonance spectroscopy of the prostate - Abstract February 7, 2012

A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radioth February 7, 2012

High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: Cancer control and toxicity outcomes - Abstract February 7, 2012

GU Cancers Symposium 2012 - Empiric antibiotics for an elevated PSA: A randomized, prospective multiinstitutional trial - Session Highlights February 7, 2012

FDA approves Bayer radium-223 chloride expanded access program February 7, 2012

Study shows an investigational urine test can predict high-risk prostate cancer in men who choose ‘watchful waiting’ February 7, 2012

Common genetic variants in prostate cancer risk prediction - results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3) - Abstract February 6, 2012

When is elective pelvic lymph node irradiation indicated in definitive radiotherapy for localized prostate cancer? - Abstract February 6, 2012

Page 1327 of 1447